Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-02-01 6:10 pm Purchase | 13G | CARDIFF ONCOLOGY INC CRDF | Avidity Partners Management LP | 2,153,600 6.1% | 2,153,600 (New Position) | View |
| 2020-12-30 2:33 pm Purchase | 13G | ONCOSEC MED INC PAR $0.000 ONCS | Avidity Partners Management LP | 1,690,000 6% | 1,690,000 (New Position) | View |
| 2020-12-28 4:48 pm Purchase | 13G | GRITSTONE BIO INC GRTS | Avidity Partners Management LP | 4,546,814 9.9% | 4,546,814 (New Position) | View |
| 2020-12-23 4:15 pm Purchase | 13G | SCYNEXIS INC SCYX | Avidity Partners Management LP | 1,097,254 9.9% | 1,097,254 (New Position) | View |
| 2020-12-23 4:09 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Avidity Partners Management LP | 1,337,413 5.6% | 1,337,413 (New Position) | View |
| 2020-11-04 5:05 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 2,600,000 6.7% | 2,600,000 (New Position) | View |
| 2020-03-11 7:31 pm Purchase | 13G | SUNESIS PHARMACEUTICALS INC CO SNSS | Avidity Partners Management LP | 4,951,925 4.4% | 4,951,925 (New Position) | View |